An additional notable finding from this study was that the absence of specialist care was associated with higher healthcare costs among patients with MPNs.
This study separately evaluated the impact of depression/antidepressant use on the QOL and OS of cohorts of patients undergoing allogeneic or autologous HSCT.
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Previous mostly retrospective/observational studies evaluated low-dose aspirin administered once daily in the setting of ET. In this study, the more frequent dosing was found optimal.
Identification of the underlying pattern for ruxolitinib failure in patients with myelofibrosis is a significant factor in determining appropriate treatment.